Abstract：Objective To investigate the effects of recombinant human growth hormone (rhGH) on the morphology and function of the left cardiac ventricle in young rats with dilated cardiomyopathy (DCM), and to evaluate the efficacy and safety of rhGH in the treatment of DCM. Methods Sixty male Sprague-Dawley rats were randomly and equally assigned to control group, DCM group, and rhGH group. Furazolidone (0.25 mg/g) was given by gavage for 12 weeks to prepare the DCM model. Rats in the rhGH group received an intraperitoneal injection of rhGH (0.15 U/kg) once per day for 12 weeks, while rats in the DCM group received an equal volume of normal saline instead. Rats in the control group did not receive any treatment. Cardiac indices, serum biochemical parameters, hemodynamic indices, cardiac histopathological changes, and levels of myocardial collagen fibrils in each group were determined using Doppler echocardiography, enzyme-linked immunosorbent assay, multi-channel physiological recorder, light and electron microscopy, and picrosirius red staining plus polarization microscopy, respectively. Results Compared with the control group, rats in the DCM group had significantly increased cardiac chamber size, significantly reduced ventricular wall thickness, and significantly decreased fractional shortening (FS) and ejection fraction (EF) (PPP>0.05). There were significant differences in serum biochemical parameters and hemodynamic indices between the DCM and control groups (PPP>0.05), except for the levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3. The DCM group had a significantly higher collagen type I/collagen type III (Col I/Col III) ratio in the myocardium than the control group (PP>0.05). Conclusions rhGH plays a certain role in improvement in the morphology and function of the left cardiac ventricle in young rats with DCM.
CHENG Sheng-Quan,QIANG Huan,FU Rong et al. Improvement in cardiac morphology and function in young rats with dilated cardiomyopathy by recombinant human growth hormone[J]. CJCP, 2015, 17(5): 508-514.
Vijayakumar A, Novosyadlyy R, Wu Y, et al. Biological effects of growth hormone on carbohydrate and lipid metabolism[J]. Growth Horm IGF Res, 2010, 20(1): 1-7.
Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction[J]. Proc Natl Acad Sci U S A, 2010, 107(6): 2604-2609.
Osterziel KJ, Ranke MB, Strohm O, et al. The somatotrophic system in patients with dilated cardiomyopthy:relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function[J]. Clin Endocri, 2000, 53(1): 61-68.
[11]
Dreifuss P. Dilated cardiomyopathy and growth hormone[J]. Z Kardiol, 2002, 91 (12): 973-977.
[12]
Perrot A, Ranke MB, Dietz R, et al. Growth hormone treatment in dilated cardiomyopathy[J]. J Cardiac Surg, 2001, 16(2): 127-131.
[13]
Adamopoulos S, Parissis JT, Georgiadis M, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble fas/souble fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy[J]. Am Heart J, 2002, 144(2): 359-364.
[14]
Jose VJ, Zechariah TU, George P, et al. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study[J]. Indian Heart J, 1999, 51(2): 183-185.
Wu Y, Tobias AH, Bell K, et al. Cellular and molecular mechanisms of systolic and diastolic dysfunction in an avian model of dilated cardiomyopathy[J]. J Mol Cell Cardiol, 2004, 15(37): 111-119.
[17]
Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, et al. The complete sequence of mtDNA genes in idiopathic dilated cardiomyopathy shows novel missense and tRNA mutations[J]. J Card Fail, 2000, 6(4): 321-329.
Borgarelli M, Tarducci A, Tidholm A, et al. Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy[J]. Vet J, 2001, 162(3): 182-195.
[20]
Morrisey EE. Rewind to recover: dedifferentiation after cardiac injury[J]. Cell Stem Cell, 2011, 4(9): 387-389.
Sukumaran V, Watanabe K, Veeraveedu PT, et al. Beneficial effects of olmesartan,an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy[J]. Exp Biol Med, 2010, 235(11): 1338-1346.
[23]
Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertohic cardiomypathy[J]. Circulation, 2001, 104(3): 317-324.
[24]
Li TS, Takahashi M, Suzuki R, et al. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinilammatory mechanism rather than by the induction of angiogenesis[J]. Ann Thorac Surg, 2006, 81(6): 2217-2225.
[25]
Martin J, Denver R, Bailey, et al. In vitro inhibitory effects of atorvastatin on cardiac fibmblasts:implications for ventrieular remodeling[J]. Clin Exp Pharnuwol Physiol, 2005, 32(9): 697-701.
